Targeted drug delivery is often critical in clinical treatments.
Ideally, such delivery would be automatically responsive to physiologic
parameters. ALZA, Durect, and other companies have made considerable
investments toprovide such responsive dosing. More recently, monoclonal
antibodies tagged with radioactive cancer treatment moieties have been
developed to provide more focused treatment of cancers, sparing normal
cells from these potent toxins. Implantable insulin pumps have been
developed to provide a more natural philological level of insulin to
This new nanomachine provides biomolecularconcentration dependent release of signaling molecules, drugs, or imaging agents. This new nanomachine, which uses the binding forces of an analyte to bend a component in a nano-device, will detect with great specificity anyantigenic bimolecular and transduce that signal into the release ofsecondary species. The secondary species need not be antigenic and couldinclude proteins, small molecules, haptens, imaging agents, nanoparticles,polymers, etc. The antigenic nature of the detection makes the devicebroadly applicable. The device is capable of operation in physiologicsolutions and requires no external power source. This fundamentalarchitecture exerts mechanical forces on a coupled delivery vehicle that contains a secondary species when the presence of a biomolecular species is detected.